Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

tanibirumab

A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background VEGF is a highly selective mitogen that serves as the central regulator of tumor angiogenesis by mediating endothelial… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2017
2017
SummaryBackground Tanibirumab is a fully human monoclonal antibody to vascular endothelial growth factor receptor 2 (VEGFR-2). We… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2017
2017
e13522Background: Treatment of recurrent GBM remains a challenge. The VEGF signal transduction pathway is upregulated in GBM. We… Expand
Is this relevant?
Review
2016
Review
2016
ABSTRACT Introduction: Anti-angiogenetic agents are currently the standard of care in metastatic CRC patients. Bevacizumab… Expand
Is this relevant?
2015
2015
2522 Background: Tanibirumab is a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 (VEGFR-2… Expand
Is this relevant?
2014
2014
PURPOSE The study investigated the effect of intravitreally administered tanibirumab, a fully human monoclonal antibody against… Expand
Is this relevant?
Review
2011
Review
2011
  • S. Lee
  • Archives of pharmacal research
  • 2011
  • Corpus ID: 20326597
Vascular endothelial growth factor (VEGF) binds to its receptor (VEGFR) and stimulates angiogenesis, an important step in tumor… Expand
  • figure 1
  • figure 2
Is this relevant?